DBV Technologies announced Phase III success for its epicutaneous peanut allergy patch in a trial enrolling more than 650 children, a milestone that sets the company up for another FDA submission after prior regulatory back‑and‑forth. The result revives DBV’s push to gain market approval for a non‑oral immunotherapy option targeting pediatric peanut allergy. The trial’s size and pediatric focus aim to address the unmet need for safer, adherence‑friendly desensitization therapies. DBV will prepare an updated regulatory package incorporating the Phase III data and requested next‑step meetings with the FDA. The outcome could reshape the peanut allergy treatment landscape if regulators accept the clinical benefit and safety profile; payers and allergists will weigh real‑world adherence and long‑term desensitization durability when considering adoption.